Minims Oxybuprocaine Hydrochloride 0.4%
Minims Oxybuprocaine Hydrochloride 0.4% Uses, Dosage, Side Effects, Food Interaction and all others data.
Minims Oxybuprocaine Hydrochloride 0.4% is a local anaesthetic. It may be less irritating than tetracaine, and the onset and duration of action are similar to tetracaine. Minims Oxybuprocaine Hydrochloride 0.4% binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.
Minims Oxybuprocaine Hydrochloride 0.4% is a local anaesthetic. It may be less irritating than tetracaine, and the onset and duration of action are similar to tetracaine.
Trade Name | Minims Oxybuprocaine Hydrochloride 0.4% |
Generic | Oxybuprocaine |
Oxybuprocaine Other Names | Benoxinate, Oxibuprocaina, Oxybucaine, Oxybuprocaine, Oxybuprocainum, Oxyriprocaine |
Type | |
Formula | C17H28N2O3 |
Weight | Average: 308.4158 Monoisotopic: 308.209992772 |
Groups | Approved, Investigational |
Therapeutic Class | Ocular perioperative drugs |
Manufacturer | |
Available Country | Malta, United Kingdom |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Used to temporarily numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed.
Minims Oxybuprocaine Hydrochloride 0.4% is also used to associated treatment for these conditions: Local Anesthesia of the Mouth
How Minims Oxybuprocaine Hydrochloride 0.4% works
Minims Oxybuprocaine Hydrochloride 0.4% binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.
Dosage
Minims Oxybuprocaine Hydrochloride 0.4% dosage
Use as a 0.4% solution in short ophthalmic procedures. Instil 1 drop into the conjunctival sac to allow tonometry after 60 sec; a further drop after a 90 sec interval produces sufficiReduce systemic absorption by compressing the lacrimal sac at the medial canthus for a minute during and following instillation. Heart block; epilepsy, impaired cardiac conduction, myasthenia gravis; not to be applied to inflamed, infected tissues or damaged mucosa. Protect anaesthetised eye from dust and bacterial contamination; cornea may be damaged by prolonged application. Do not drive until normal vision restored.ent anaesthesia for the fitting of contact lenses; 3 drops at 90 sec intervals produces sufficient anaesthesia after 5 min for a foreign body to be removed from the corneal epithelium or for incision of a meibomian cyst through the conjunctiva.
Side Effects
Hypersensitivity reactions; transient stinging and blurring of vision; excitation of CNS; muscle twitching and tremors; convulsions.
Precaution
Reduce systemic absorption by compressing the lacrimal sac at the medial canthus for a minute during and following instillation. Heart block; epilepsy, impaired cardiac conduction, myasthenia gravis; not to be applied to inflamed, infected tissues or damaged mucosa. Protect anaesthetised eye from dust and bacterial contamination; cornea may be damaged by prolonged application. Do not drive until normal vision restored.
Food Interaction
No interactions found.Pregnancy & Breastfeeding use
Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Innovators Monograph
You find simplified version here Minims Oxybuprocaine Hydrochloride 0.4%
Minims Oxybuprocaine Hydrochloride 0.4% contains Oxybuprocaine see full prescribing information from innovator Minims Oxybuprocaine Hydrochloride 0.4% Monograph, Minims Oxybuprocaine Hydrochloride 0.4% MSDS, Minims Oxybuprocaine Hydrochloride 0.4% FDA label